Hydroquinone
Tri-luma (hydroquinone) is a small molecule pharmaceutical. Hydroquinone was first approved as Tri-luma on 2002-01-18. It is used to treat hyperpigmentation in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Combinations
Tri-luma
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 141010 hydroquinone 4% | unapproved drug other | 2020-07-02 |
| 141011 hydroquinone 6% | unapproved drug other | 2020-07-02 |
| 141016 hydrocortisone 0.5% / hydroquinone 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
| 141017 hydrocortisone 0.5% / hydroquinone 6% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
| 141030 hydroquinone 8% | unapproved drug other | 2020-07-02 |
| 141055 hydroquinone 6% | unapproved drug other | 2020-07-02 |
| 141060 hydrocortisone 0.5% / hydroquinone 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
| 141061 hydrocortisone 0.5% / hydroquinone 8% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
| 141067 hydroquinone 8% | unapproved drug other | 2020-07-02 |
| advanced dual complex fade | OTC monograph not final | 2009-02-25 |
Show 139 more
Indications
FDA
EMA
Show 2 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanosis | D008548 | EFO_0003963 | L81.1 | — | — | — | 4 | — | 4 |
Indications Phases 3
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hydroquinone |
| INN | — |
| Description | Hydroquinone is a benzenediol comprising benzene core carrying two hydroxy substituents para to each other. It has a role as a cofactor, a carcinogenic agent, an Escherichia coli metabolite, a human xenobiotic metabolite, a skin lightening agent, an antioxidant and a mouse metabolite. It is a benzenediol and a member of hydroquinones. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Oc1ccc(O)cc1 |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Hydroquinone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,921 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
910 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use